Latest news with #EQA
The Star
29-05-2025
- The Star
Company, two directors charged with dumping hazardous waste in PD
SEREMBAN: A company and its two directors, including a former state Environment Department (DOE) deputy director, claimed trial at the Sessions Court here to a charge of illegally dumping hazardous wastes. Nature Energy Products Sdn Bhd and its directors S. Sivanathiran, 62, who was former state DOE deputy director, and Chan Kwai Soon, 47, pleaded not guilty after the charge was read to them before Judge Mohamad Kamil Nizam. Chan also represented the company. They were charged with dumping the waste (code SW322) on Lot 11224, in Jimah, Port Dickson at around 4.30pm on Oct 14, 2024. SW322 refers to "waste of non-halogenated organic solvents". This classification falls under the broader category of hazardous waste and requires specific handling and disposal procedures. The company and both directors were charged under Section 34B(1)(a) of the Environmental Quality Act 1974 (EQA) which prohibits the placement, deposit, or disposal of scheduled waste without the approval of the Director-General of Environment. Section 34B(1)(a) directly addresses the illegal disposal of scheduled wastes, which are hazardous materials designated by the government. Offenders can be jailed up to five years and fined between RM100,000 and RM10mil upon conviction. Deputy Public Prosecutor from the DOE Nurliyana R. Azmi then told the court the offence was non-bailable but left it to the court's discretion. She said in the event the court allowed bail, her team proposed an amount of RM50,000 for each director. She also asked the court to order the directors to surrender their passports and to not contact prosecution witnesses. Lawyer Ramzani Idris, who represented the accused, then asked the court to impose bail adding that the directors have been cooperative in the department's probe. Haresh Mahadevan, who assisted Ramzani, then got up to say that the directors should not be asked to surrender their passports as both were businessmen who travelled often. Sivanathiran, he added, was a retired government servant and was not a flight risk. He said if the court were to impose bail, an amount of RM5,000 was sufficient. Judge Mohamad Kamil then set bail at RM9,000 each for the directors and fixed July 3 for mention. He also ordered the duo to report to the nearest DOE office monthly until the case is disposed of and to stay away from prosecution witnesses.
The Star
21-05-2025
- Business
- The Star
Palm oil mill fined RM90,000 for polluting Melaka waterways
MELAKA: A crude palm oil mill in Kuala Linggi has been fined RM90,000 by the Sessions Court in Ayer Keroh here for three offences of failing to comply with licensing conditions set by the Melaka Environment Department. The department's director Rosli Mustafa said that the court imposed a fine of RM30,000 for each charge on the company on Wednesday (May 21). He said the representative of the company present in court paid the fines the same day. "The charges against the premises of the accused involved failure to comply with licence conditions issued under Section 18(1) of the Environmental Quality Act (EQA) 1974. "Investigations found that there was a leak from the effluent discharge channel at the premises of the company, which then entered inland waterways and led to complaints of water pollution. "The court imposed a fine of RM90,000 for the three charges under Section 16(1) of the EQA, punishable under Section 16(2) of the same Act," he said.
Yahoo
09-04-2025
- Business
- Yahoo
Microbix Exhibiting at ESCMID Global 2025
Microbix Showcasing novel QAPs, Customer Presenting Pilot EQA Program Results MISSISSAUGA, Ontario, April 09, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending and exhibiting at ESCMID Global 2025 and that a customer and collaborator will be presenting results of a pilot External Quality Assessment (EQA) program enabled by Microbix Quality Assessment Products (QAPs™). ESCMID Global is the Congress of the European Society of Clinical Microbiology and Infectious Diseases, taking place in Vienna, Austria April 11-15, 2025. ESCMID Global assembles leading experts in infectious diseases and clinical microbiology to exchange ideas and explore the latest innovations. The Congress consists of five days packed with keynote lectures, oral sessions, workshops, symposia, meet-the-expert sessions, and poster presentations, making it the world's most eminent event in the field of infection. Visit for further information. At ESCMID Global, Microbix will be showcasing its QAPs innovations for helping to ensure the accuracy of diagnostic tests, including for bacterial, viral, and parasitic diseases, and in multiple formats, such as liquid-vials and on Copan® FLOQSwabs®. Additionally, Microbix will be presenting information about its QAPs that support cutting-edge assays relating to multiplex/syndromic, viral variant, antimicrobial resistance, genetics, oncology, and molecular pathology tests. The Microbix team looks forward to meeting with current and prospective clients and determining how best to support their QMS needs. Also at ESCMID Global, Labquality EQAS by Aurevia (a Microbix customer and collaborator), is presenting a poster titled 'Neither Nor or Norovirus GI/GII? Good Consensus in International EQA Pilot Study for Norovirus Antigen Detection.' Authored by Heidi Berghäll, EQA Solutions Manager R&D, and her colleagues at Aurevia, the poster provides results of a pilot EQA scheme to support rapid point-of-care antigen-based tests for Norovirus, a common and highly-contagious cause of gastroenteritis, sometimes also known as Norwalk virus or the stomach-flu. Microbix is pleased to have supported the creation of this Labquality EQAS program with FLOQSwab-formatted QAPs that are specific for antigen-based Norovirus tests. Prior to the creation of these novel QAPs, Microbix believes that no suitable swab-based whole-process workflow controls existed to provide quality management of antigen-tests for Norovirus. Microbix is pleased to address Aurevia's requirements for this EQA program and likewise demonstrate its skills in creating stable and effective controls using even the most challenging antigen materials. Enquiries regarding the EQA program being developed by Aurevia to qualify and support point-of-care antigen-based testing for Noroviruses should be directed to info@ or via the website Purchase enquiries for these or other Microbix QAPs can be e-mailed to About Microbix Biosystems Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues now targeting C$ 2.0 million or more per month. It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products. Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada. Forward-Looking InformationThis news release includes 'forward-looking information,' as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Aurevia, Labquality EQAS or its EQA schemes, the Poster, the Norovirus QAPs, or their relevance, Microbix's or others' products or services, business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its presentations, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity or timeliness of delivery), currency exchange rates, maintaining adequate working capital or raising new capital on acceptable terms or at all, and other similar statements about anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. Microbix cautions that all forward-looking information is inherently uncertain and actual performance may be affected by many material factors, some of which are beyond its control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent Microbix's judgement as of the date of this new release, and it is under no obligation to update or alter any forward-looking information. Please visit or for recent Microbix news and filings. For further information, please contact Microbix at: Cameron Groome, CEO(905) 361-8910 Jim Currie, CFO(905) 361-8910 Deborah Honig, Investor RelationsAdelaide Capital Markets(647) 203-8793 ir@ Copyright © 2025 Microbix Biosystems Inc. Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix Biosystems FLOQ®, and FLOQSwab® are trademarks of Copan Italia companies' names and products are protected by their respective in to access your portfolio
